Hepion Pharmaceuticals, Inc.
HEPA · OTCMCIK 1583771fmd_1Y0EAZTCH6A1RXK2NMVZE7PA64Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2026, 52 periods
| Line item | FY2017 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 0 | 0 | 0 | – | – |
| Research and development | – | 13 | 8 | 3 | 12 | 20 | 33 | 36 | 12 | 0 |
| Total operating expenses | 21 | – | 15 | 8 | 20 | 30 | 45 | 48 | 19 | 4 |
| Operating income | – | (21) | (15) | (8) | (20) | (30) | (45) | (48) | (19) | (4) |
| Interest expense | – | – | 0 | 1 | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | 4 | – | – | – | – | – | – | – | – | – |
| Income before taxes | – | (15) | (10) | (8) | (20) | (33) | (45) | (49) | (16) | (8) |
| Income tax expense | – | (2) | (1) | (1) | 0 | 0 | (3) | (0) | (3) | – |
| Net income from continuing operations | – | (13) | (9) | (7) | (20) | (33) | (42) | (49) | (13) | – |
| Net income | (15) | – | (9) | (7) | (20) | (33) | (42) | (49) | (13) | (8) |
| Net income to common shareholders | (15) | – | (18) | (12) | (20) | (33) | (45) | (49) | – | – |